NCT04771806 Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma
| NCT ID | NCT04771806 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Malignant Glioma |
| Study Type | OBSERVATIONAL |
| Enrollment | 80 participants |
| Start Date | 2019-04-01 |
| Primary Completion | 2027-02-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 80 participants in total. It began in 2019-04-01 with a primary completion date of 2027-02-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study examines whether repeated magnetic resonance imaging (MRI)s scan helps identify changes in the tumor during radiation and chemotherapy treatment in patients with high grade glioma. Additional MRIs scan may help researchers to see changes in the status of the disease. Seeing these changes may result in changes to the treatment plan.
Eligibility Criteria
Inclusion Criteria: * All patients with histologic confirmation of high grade glioma * Patients must be age \>= 18 years * Patients must sign informed consent indicating that they are aware of the investigational nature of this study in keeping with the policies of the hospital. The only acceptable consent form is the one attached at the end of this protocol, and has been approved and amended by the MD Anderson Cancer Center (MDACC) Institutional Review Board (IRB) * Patients must have Karnofsky performance status (KPS) \>= 60 * Patients must be able to obtain an MRI scan with gadolinium contrast * Female patients of childbearing age must not be pregnant as determined with a serum beta human chorionic gonadotropin (HCG) no greater than 14 days prior to study registration, or breastfeeding. (The exclusion is made because gadolinium may be teratogenic in pregnancy). Female patients who consent to participate in the study will need to use contraceptive methods for the duration of the study
Contact & Investigator
Caroline Chung
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT04771806 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Malignant Glioma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04771806 currently recruiting?
Yes, NCT04771806 is actively recruiting participants. Contact the research team at cchung3@mdanderson.org for enrollment information.
Where is the NCT04771806 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT04771806 clinical trial?
NCT04771806 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Caroline Chung at M.D. Anderson Cancer Center. The trial plans to enroll 80 participants.